ホーム › 非ホジキンリンパ腫 › イリノイ州 › Chicago
Chicago、ILにおける非ホジキンリンパ腫の臨床試験
Chicagoとその周辺地域（約30マイル以内）の拠点で、非ホジキンリンパ腫に関する18件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
被験者募集中第2相
- Cancer Treatment Centers of America-Chicago, Chicago
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
被験者募集中第1相
- The University of Chicago Medical Center (UCMC), Chicago
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
被験者募集中第2相
- Research Site, Chicago
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
被験者募集中第1/2相
- Lurie Children's Hospital-Chicago, Chicago
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
被験者募集中第1/2相
- University of Chicago Medical Center, Chicago
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
被験者募集中第1相
- The David and Etta Jonas Center for Cellular Therapy, Chicago
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
被験者募集中観察研究
- Robert H Lurie Cancer Center, Chicago
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
被験者募集中第3相
- Northwestern, Chicago
- University of Chicago, Chicago
DALY II USA/ MB-CART2019.1 for DLBCL
被験者募集中第2相
- Robert H Lurie Cancer Center, Chicago
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
被験者募集中第1相
- University of Illinois at Chicago, Chicago
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
被験者募集中観察研究
- Northwestern Memorial Hospital, Chicago
- Rush University Medical Center, Chicago
- University of Illinois at Chicago, Chicago
- 他2件
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
被験者募集中第1相
- University of Chicago, Chicago
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
被験者募集中第1/2相
- Northwestern Memorial Hospital, Chicago
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
被験者募集中観察研究
- John H Stroger Jr Hospital of Cook County, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
被験者募集中第4相
- Northwestern University, Chicago
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
被験者募集中第4相
- Northwestern University, Chicago
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
被験者募集中第1相
- Northwestern Memorial Hospital, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Chicago
他の都市における非ホジキンリンパ腫の試験
- New York City, NY31件の研究
- Houston, TX31件の研究
- Boston, MA26件の研究
- Nashville, TN21件の研究
- Philadelphia, PA20件の研究
- Baldwin Park, CA19件の研究
- Washington, DC18件の研究
- Atlanta, GA18件の研究
- Milwaukee, WI18件の研究
- Columbus, OH18件の研究
- Dallas, TX17件の研究
- Seattle, WA16件の研究
Chicagoにおける他の研究
- 非小細胞肺癌61件の研究
- 乳がん59件の研究
- がん（全種類）51件の研究
- 転移性癌45件の研究
- 前立腺がん45件の研究
- 肺がん41件の研究
- 肥満症41件の研究
- 卵巣がん36件の研究
- 大腸癌34件の研究
- 脳卒中34件の研究
- 心不全31件の研究
- 過体重29件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。